Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.

Yang M, Henderson AD, Anand IS, Desai AS, Lam CSP, Maggioni AP, Martinez FA, Rouleau JL, Swedberg K, Vaduganathan M, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Rizkala A, Lewis EF, Jhund PS, Solomon SD, McMurray JJV

Open source

DOI: 10.1093/ehjcvp/pvaf064
Published: 2025 Nov 4
Container: European heart journal. Cardiovascular pharmacotherapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ehjcvp/pvaf064,
  title = {Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.},
  author = {Yang M and Henderson AD and Anand IS and Desai AS and Lam CSP and Maggioni AP and Martinez FA and Rouleau JL and Swedberg K and Vaduganathan M and van Veldhuisen DJ and Zannad F and Zile MR and Packer M and Rizkala A and Lewis EF and Jhund PS and Solomon SD and McMurray JJV},
  year = {2025},
  journal = {European heart journal. Cardiovascular pharmacotherapy},
  doi = {10.1093/ehjcvp/pvaf064},
  url = {https://doi.org/10.1093/ehjcvp/pvaf064}
}

RIS

TY  - JOUR
TI  - Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.
AU  - Yang M
AU  - Henderson AD
AU  - Anand IS
AU  - Desai AS
AU  - Lam CSP
AU  - Maggioni AP
AU  - Martinez FA
AU  - Rouleau JL
AU  - Swedberg K
AU  - Vaduganathan M
AU  - van Veldhuisen DJ
AU  - Zannad F
AU  - Zile MR
AU  - Packer M
AU  - Rizkala A
AU  - Lewis EF
AU  - Jhund PS
AU  - Solomon SD
AU  - McMurray JJV
PY  - 2025
JO  - European heart journal. Cardiovascular pharmacotherapy
DO  - 10.1093/ehjcvp/pvaf064
UR  - https://doi.org/10.1093/ehjcvp/pvaf064
ER  -

APA

M, Y., AD, H., IS, A., AS, D., CSP, L., AP, M., FA, M., JL, R., K, S., M, V., DJ, V. V., F, Z., MR, Z., M, P., A, R., EF, L., PS, J., SD, S., & JJV, M. (2025). Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.. European heart journal. Cardiovascular pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvaf064

Source records

pubmed · retrieved 2026-09-26T21:02:24.912Z